DE102005034974A1 - Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen - Google Patents
Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen Download PDFInfo
- Publication number
- DE102005034974A1 DE102005034974A1 DE102005034974A DE102005034974A DE102005034974A1 DE 102005034974 A1 DE102005034974 A1 DE 102005034974A1 DE 102005034974 A DE102005034974 A DE 102005034974A DE 102005034974 A DE102005034974 A DE 102005034974A DE 102005034974 A1 DE102005034974 A1 DE 102005034974A1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- cyclohex
- dimethylamino
- crystalline form
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 title claims description 21
- XQUUVZDIAMCEHA-UHFFFAOYSA-N n,n-dimethyl-1-(1-phenylcyclohexyl)methanamine Chemical compound C=1C=CC=CC=1C1(CN(C)C)CCCCC1 XQUUVZDIAMCEHA-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- DYUBYVPYECCFFH-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[2-[(dimethylamino)methyl]cyclohexyl]phenol Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CC1CCCCC1C1=CC=CC(O)=C1 DYUBYVPYECCFFH-BTJKTKAUSA-N 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 70
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 60
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 239000000725 suspension Substances 0.000 claims description 28
- ARKPCUWVXCOCEC-UHFFFAOYSA-N C(C=C/C(=O)O)(=O)O.CN(C1C(CCCC1)(C=1C=C(C=CC1)O)C)C Chemical compound C(C=C/C(=O)O)(=O)O.CN(C1C(CCCC1)(C=1C=C(C=CC1)O)C)C ARKPCUWVXCOCEC-UHFFFAOYSA-N 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 23
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 20
- 238000002441 X-ray diffraction Methods 0.000 claims description 20
- 239000011976 maleic acid Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 17
- 239000011877 solvent mixture Substances 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 16
- JIRYWFYYBBRJAN-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]cyclohexyl]phenol Chemical class CN(C)CC1CCCCC1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-UHFFFAOYSA-N 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 238000001237 Raman spectrum Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000012298 atmosphere Substances 0.000 claims description 8
- 239000011261 inert gas Substances 0.000 claims description 5
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 239000000243 solution Substances 0.000 description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- 239000000843 powder Substances 0.000 description 31
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 239000003814 drug Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- -1 alkali metal bicarbonates Chemical class 0.000 description 16
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 16
- 238000000113 differential scanning calorimetry Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000002425 crystallisation Methods 0.000 description 14
- 230000008025 crystallization Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- DYUBYVPYECCFFH-HHJQJOJISA-N (z)-but-2-enedioic acid;3-[(1r,2r)-2-[(dimethylamino)methyl]cyclohexyl]phenol Chemical compound OC(=O)\C=C/C(O)=O.CN(C)C[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 DYUBYVPYECCFFH-HHJQJOJISA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 8
- 229960003920 cocaine Drugs 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 229960002715 nicotine Drugs 0.000 description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 8
- 208000011117 substance-related disease Diseases 0.000 description 8
- JIRYWFYYBBRJAN-ZFWWWQNUSA-N faxeladol Chemical compound CN(C)C[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-ZFWWWQNUSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 206010013663 drug dependence Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 150000002688 maleic acid derivatives Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000002076 thermal analysis method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- VYSLNAXTLKZELH-UHFFFAOYSA-N 3-[2-(dimethylamino)-1-methylcyclohexyl]phenol;hydrochloride Chemical compound Cl.CN(C)C1CCCCC1(C)C1=CC=CC(O)=C1 VYSLNAXTLKZELH-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000005079 FT-Raman Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-Lactic acid Natural products C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910052756 noble gas Inorganic materials 0.000 description 2
- 150000002835 noble gases Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 238000004441 surface measurement Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- PPQGKIDZESAVRG-UHFFFAOYSA-N 2-(decanoylamino)ethanesulfonic acid Chemical compound CCCCCCCCCC(=O)NCCS(O)(=O)=O PPQGKIDZESAVRG-UHFFFAOYSA-N 0.000 description 1
- GQIKWWYWUPOJPW-UHFFFAOYSA-N 2-(octanoylamino)ethanesulfonic acid Chemical compound CCCCCCCC(=O)NCCS(O)(=O)=O GQIKWWYWUPOJPW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- SLOIWIHZXQWWIY-SLHAJLBXSA-N 3-[(1r,2r)-2-[(dimethylamino)methyl]cyclohexyl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 SLOIWIHZXQWWIY-SLHAJLBXSA-N 0.000 description 1
- SLOIWIHZXQWWIY-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]cyclohexyl]phenol;hydrochloride Chemical compound Cl.CN(C)CC1CCCCC1C1=CC=CC(O)=C1 SLOIWIHZXQWWIY-UHFFFAOYSA-N 0.000 description 1
- YWKSINPSASCIMZ-UHFFFAOYSA-N 4,5-dimethyl-4,5-dihydro-1h-imidazole Chemical compound CC1NC=NC1C YWKSINPSASCIMZ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000398147 Aleurodiscus amorphus Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- KCFRUUYAXCDZNZ-UHFFFAOYSA-N N-dodecanoyltaurine Chemical compound CCCCCCCCCCCC(=O)NCCS(O)(=O)=O KCFRUUYAXCDZNZ-UHFFFAOYSA-N 0.000 description 1
- LPDJCYFKKSLKRO-UHFFFAOYSA-N N-hexadecanoyltaurine Chemical compound CCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O LPDJCYFKKSLKRO-UHFFFAOYSA-N 0.000 description 1
- LMIJIHJZVURGQK-UHFFFAOYSA-N N-stearoyltaurine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O LMIJIHJZVURGQK-UHFFFAOYSA-N 0.000 description 1
- XPZFMHCHEWYIGE-UHFFFAOYSA-N N-tetradecanoyltaurine Chemical compound CCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O XPZFMHCHEWYIGE-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000003484 crystal nucleating agent Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CSMFSDCPJHNZRY-UHFFFAOYSA-M decyl sulfate Chemical compound CCCCCCCCCCOS([O-])(=O)=O CSMFSDCPJHNZRY-UHFFFAOYSA-M 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940094506 lauryl betaine Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- UZZYXUGECOQHPU-UHFFFAOYSA-M n-octyl sulfate Chemical compound CCCCCCCCOS([O-])(=O)=O UZZYXUGECOQHPU-UHFFFAOYSA-M 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940067739 octyl sulfate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001444 polymaleic acid Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- CSMFSDCPJHNZRY-UHFFFAOYSA-N sulfuric acid monodecyl ester Natural products CCCCCCCCCCOS(O)(=O)=O CSMFSDCPJHNZRY-UHFFFAOYSA-N 0.000 description 1
- UZZYXUGECOQHPU-UHFFFAOYSA-N sulfuric acid monooctyl ester Natural products CCCCCCCCOS(O)(=O)=O UZZYXUGECOQHPU-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (40)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005034974A DE102005034974A1 (de) | 2005-07-22 | 2005-07-22 | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| CNA2006800267177A CN101228110A (zh) | 2005-07-22 | 2006-07-20 | 3-[2-（二甲基氨基）甲基-（环己-1-基）]-苯酚马来酸盐及其结晶形式 |
| EP06776327A EP1907351A1 (de) | 2005-07-22 | 2006-07-20 | Hcl-polymorphe von 3 - ( 2- (dimethylamino) methyl- ( cyclohex-i-yl) ) phenol |
| DE502006003728T DE502006003728D1 (de) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
| JP2008521894A JP5205259B2 (ja) | 2005-07-22 | 2006-07-20 | ３−（２−（ジメチルアミノ）メチル−（シクロヘキシ−１−イル）−フェノール−マレイン酸塩及びその結晶形 |
| SI200630355T SI1881956T1 (sl) | 2005-07-22 | 2006-07-20 | 3-(2-(dimetilamino)metil-(cikloheks-1-il))fenol-maleat in njegove kristalne oblike |
| RU2008106455/04A RU2434845C2 (ru) | 2005-07-22 | 2006-07-20 | Малеат 3-[2-(диметиламино)метил-(циклогекс-1-ил)]фенола и его кристаллические формы |
| PT06776325T PT1881956E (pt) | 2005-07-22 | 2006-07-20 | Maleato de 3-[2-(dimetilamino)metil(ciclo-hex-1-il)]fenol e suas formas cristalinas |
| PL06776325T PL1881956T3 (pl) | 2005-07-22 | 2006-07-20 | Maleinian 3-[2-(dimetyloamino)metylo-(cykloheks-1-ylo)]-fenolu i jego postacie krystaliczne |
| KR1020087004229A KR20080033436A (ko) | 2005-07-22 | 2006-07-20 | 3-(2-(디메틸아미노)메틸-(사이클로헥스-1-일))페놀말레에이트 및 이의 결정형 |
| EP06776325A EP1881956B1 (de) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
| HK08107521.5A HK1112612B (en) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl(cyclohex-1-yl))phenol maleate and its crystalline forms |
| JP2008521896A JP5323480B2 (ja) | 2005-07-22 | 2006-07-20 | ３−［２−（ジメチルアミノ）メチル−（シクロヘキシ−１−イル）］−フェノールのＨＣｌ多形体 |
| PCT/EP2006/007163 WO2007009794A1 (de) | 2005-07-22 | 2006-07-20 | Hcl-polymorphe von 3 - ( 2- (dimethylamino) methyl- ( cyclohex-i-yl) ) phenol |
| HR20090412T HRP20090412T1 (hr) | 2005-07-22 | 2006-07-20 | 3-(2-(dimetlamino)metil-(cikloheks-1-il))fenol-maleat i njegovi kristalni oblici |
| EP10014791A EP2336103A3 (de) | 2005-07-22 | 2006-07-20 | HCL-Polymorphe von 3-[2-(Dimethylamino)methyl-(cyclohex-1-yl)]phenol |
| AT06776325T ATE431332T1 (de) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phen l-maleat und dessen kristalline formen |
| ES06776325T ES2326493T3 (es) | 2005-07-22 | 2006-07-20 | Maleato de 3-(2-(dimetilamino)metil-(ciclohex-1-il))fenol y sus formas cristalinas. |
| CA002615926A CA2615926A1 (en) | 2005-07-22 | 2006-07-20 | 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate and the crystalline forms thereof |
| PCT/EP2006/007160 WO2007009792A1 (de) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
| CA002615742A CA2615742A1 (en) | 2005-07-22 | 2006-07-20 | Hcl polymorphs of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol |
| PE2006000873A PE20070368A1 (es) | 2005-07-22 | 2006-07-20 | Sal maleato del compuesto 3-[2-(dimetilamino)metil-(ciclohexil)]-fenol y sus formas cristalinas |
| MX2008000743A MX2008000743A (es) | 2005-07-22 | 2006-07-20 | Maleato de 3-(2-(dimetilamino)metil(ciclohex-1-il)) fenol y sus formas cristalinas. |
| AU2006271856A AU2006271856B2 (en) | 2005-07-22 | 2006-07-20 | 3-(2-(Dimethylamino)methyl(cyclohex-1-yl))phenol maleate and its crystalline forms |
| BRPI0614057-2A BRPI0614057A2 (pt) | 2005-07-22 | 2006-07-20 | 3-(2-(dimetilamino) metil-(ciclohex-1-il))-fenol-maleato e suas formas cristalinas |
| DK06776325T DK1881956T3 (da) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyklohex-1-YL))phenol-maleat og dennes krystal-line form |
| ARP060103155A AR057674A1 (es) | 2005-07-22 | 2006-07-21 | Sal de dimetilaminometil-fenil-ciclohexano y su forma cristalina |
| US11/491,238 US7884247B2 (en) | 2005-07-22 | 2006-07-24 | Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof |
| EC2008008088A ECSP088088A (es) | 2005-07-22 | 2008-01-08 | Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas |
| US12/016,506 US8058476B2 (en) | 2005-07-22 | 2008-01-18 | HCI polymorphs of 3-((2-(dimethylamino)methyl(cyclohex-1-yl)) phenol |
| IL188897A IL188897A (en) | 2005-07-22 | 2008-01-21 | 3-(2-(dimethylamino)methyl(cyclohex-1-yl)phenol maleate and its crystalline forms |
| NO20080826A NO20080826L (no) | 2005-07-22 | 2008-02-15 | 3-(2-(dimetylamino)metyl(cykloheks-1-yl))fenolmaleat og dets krystallinske former |
| ZA200801703A ZA200801703B (en) | 2005-07-22 | 2008-02-21 | 3-(2-(Dimethylamino)methyl(cyclohex-1-yl))phenol maleate and its crystalline forms |
| CY20091100706T CY1109208T1 (el) | 2005-07-22 | 2009-07-03 | Μηλεϊκη 3-(2-(διμεθυλαμινο) μεθυλ (κυκλοεξ-1-υλ)) φαινολη και οι κρυσταλλικες μορφες της |
| US12/627,190 US20100076085A1 (en) | 2005-07-22 | 2009-11-30 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl-(cyclohex-1-yl))phenol |
| US12/855,464 US20110046230A1 (en) | 2005-07-22 | 2010-08-12 | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof |
| US13/165,331 US20110251287A1 (en) | 2005-07-22 | 2011-06-21 | Hci polymorphs of 3-((2-(dimethylamino)methyl (cyclohex-1-yl))phenol |
| US13/419,618 US20120178809A1 (en) | 2005-07-22 | 2012-03-14 | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof |
| JP2012198012A JP2013018776A (ja) | 2005-07-22 | 2012-09-10 | ３−［２−（ジメチルアミノ）メチル−（シクロヘキシ−１−イル）］−フェノールのＨＣｌ多形体 |
| US13/874,851 US20130245125A1 (en) | 2005-07-22 | 2013-05-01 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005034974A DE102005034974A1 (de) | 2005-07-22 | 2005-07-22 | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102005034974A1 true DE102005034974A1 (de) | 2007-04-19 |
Family
ID=37084866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102005034974A Withdrawn DE102005034974A1 (de) | 2005-07-22 | 2005-07-22 | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| DE502006003728T Active DE502006003728D1 (de) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE502006003728T Active DE502006003728D1 (de) | 2005-07-22 | 2006-07-20 | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1881956B1 (https=) |
| JP (1) | JP5205259B2 (https=) |
| KR (1) | KR20080033436A (https=) |
| CN (1) | CN101228110A (https=) |
| AR (1) | AR057674A1 (https=) |
| AT (1) | ATE431332T1 (https=) |
| AU (1) | AU2006271856B2 (https=) |
| BR (1) | BRPI0614057A2 (https=) |
| CA (1) | CA2615926A1 (https=) |
| CY (1) | CY1109208T1 (https=) |
| DE (2) | DE102005034974A1 (https=) |
| DK (1) | DK1881956T3 (https=) |
| EC (1) | ECSP088088A (https=) |
| ES (1) | ES2326493T3 (https=) |
| HR (1) | HRP20090412T1 (https=) |
| IL (1) | IL188897A (https=) |
| MX (1) | MX2008000743A (https=) |
| NO (1) | NO20080826L (https=) |
| PE (1) | PE20070368A1 (https=) |
| PL (1) | PL1881956T3 (https=) |
| PT (1) | PT1881956E (https=) |
| RU (1) | RU2434845C2 (https=) |
| SI (1) | SI1881956T1 (https=) |
| WO (1) | WO2007009792A1 (https=) |
| ZA (1) | ZA200801703B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2085081A1 (de) | 2008-02-04 | 2009-08-05 | Grünenthal GmbH | 3-(2-Dimethylaminomethyl-cyclohexyl)-phenol gegen polyneuropathischen Schmerz |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI384986B (zh) * | 2007-01-17 | 2013-02-11 | Lg Life Sciences Ltd | 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物 |
| WO2009071310A1 (de) * | 2007-12-07 | 2009-06-11 | Grünenthal GmbH | Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0753506A1 (de) * | 1995-07-11 | 1997-01-15 | Grünenthal GmbH | 6-dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe |
| DE10356362A1 (de) * | 2003-11-28 | 2005-06-23 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10218862A1 (de) * | 2002-04-26 | 2003-11-06 | Gruenenthal Gmbh | Verfahren zur Chlorierung tertiärer Alkohole |
-
2005
- 2005-07-22 DE DE102005034974A patent/DE102005034974A1/de not_active Withdrawn
-
2006
- 2006-07-20 PL PL06776325T patent/PL1881956T3/pl unknown
- 2006-07-20 JP JP2008521894A patent/JP5205259B2/ja not_active Expired - Fee Related
- 2006-07-20 SI SI200630355T patent/SI1881956T1/sl unknown
- 2006-07-20 EP EP06776325A patent/EP1881956B1/de not_active Not-in-force
- 2006-07-20 MX MX2008000743A patent/MX2008000743A/es active IP Right Grant
- 2006-07-20 ES ES06776325T patent/ES2326493T3/es active Active
- 2006-07-20 WO PCT/EP2006/007160 patent/WO2007009792A1/de not_active Ceased
- 2006-07-20 PT PT06776325T patent/PT1881956E/pt unknown
- 2006-07-20 AT AT06776325T patent/ATE431332T1/de active
- 2006-07-20 RU RU2008106455/04A patent/RU2434845C2/ru not_active IP Right Cessation
- 2006-07-20 DE DE502006003728T patent/DE502006003728D1/de active Active
- 2006-07-20 DK DK06776325T patent/DK1881956T3/da active
- 2006-07-20 KR KR1020087004229A patent/KR20080033436A/ko not_active Abandoned
- 2006-07-20 BR BRPI0614057-2A patent/BRPI0614057A2/pt not_active IP Right Cessation
- 2006-07-20 CN CNA2006800267177A patent/CN101228110A/zh active Pending
- 2006-07-20 AU AU2006271856A patent/AU2006271856B2/en not_active Ceased
- 2006-07-20 HR HR20090412T patent/HRP20090412T1/hr unknown
- 2006-07-20 CA CA002615926A patent/CA2615926A1/en not_active Abandoned
- 2006-07-20 PE PE2006000873A patent/PE20070368A1/es not_active Application Discontinuation
- 2006-07-21 AR ARP060103155A patent/AR057674A1/es not_active Application Discontinuation
-
2008
- 2008-01-08 EC EC2008008088A patent/ECSP088088A/es unknown
- 2008-01-21 IL IL188897A patent/IL188897A/en not_active IP Right Cessation
- 2008-02-15 NO NO20080826A patent/NO20080826L/no not_active Application Discontinuation
- 2008-02-21 ZA ZA200801703A patent/ZA200801703B/xx unknown
-
2009
- 2009-07-03 CY CY20091100706T patent/CY1109208T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0753506A1 (de) * | 1995-07-11 | 1997-01-15 | Grünenthal GmbH | 6-dimethylaminomethyl-1-phenyl-cyclo-hexanverbindungen als pharmazeutische Wirkstoffe |
| DE10356362A1 (de) * | 2003-11-28 | 2005-06-23 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2085081A1 (de) | 2008-02-04 | 2009-08-05 | Grünenthal GmbH | 3-(2-Dimethylaminomethyl-cyclohexyl)-phenol gegen polyneuropathischen Schmerz |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006271856B2 (en) | 2012-03-01 |
| CN101228110A (zh) | 2008-07-23 |
| KR20080033436A (ko) | 2008-04-16 |
| PE20070368A1 (es) | 2007-05-12 |
| WO2007009792A1 (de) | 2007-01-25 |
| ATE431332T1 (de) | 2009-05-15 |
| AU2006271856A1 (en) | 2007-01-25 |
| BRPI0614057A2 (pt) | 2012-12-11 |
| SI1881956T1 (sl) | 2009-10-31 |
| CA2615926A1 (en) | 2007-01-25 |
| AR057674A1 (es) | 2007-12-12 |
| ZA200801703B (en) | 2009-08-26 |
| RU2434845C2 (ru) | 2011-11-27 |
| EP1881956B1 (de) | 2009-05-13 |
| JP5205259B2 (ja) | 2013-06-05 |
| PT1881956E (pt) | 2009-06-26 |
| DK1881956T3 (da) | 2009-09-07 |
| DE502006003728D1 (de) | 2009-06-25 |
| HK1112612A1 (zh) | 2008-09-12 |
| PL1881956T3 (pl) | 2009-10-30 |
| HRP20090412T1 (hr) | 2009-09-30 |
| JP2009502757A (ja) | 2009-01-29 |
| RU2008106455A (ru) | 2009-08-27 |
| IL188897A0 (en) | 2008-04-13 |
| MX2008000743A (es) | 2008-03-10 |
| ECSP088088A (es) | 2008-02-20 |
| EP1881956A1 (de) | 2008-01-30 |
| CY1109208T1 (el) | 2014-07-02 |
| ES2326493T3 (es) | 2009-10-13 |
| NO20080826L (no) | 2008-02-20 |
| IL188897A (en) | 2012-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60205742T2 (de) | Tartratsalze von 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen | |
| JP5154227B2 (ja) | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドの塩及びその調製 | |
| DE202018006384U1 (de) | Herstellung von Psilocybin, verschiedenen polymorphen Formen, Zwischenprodukten, Formulierungen und deren Verwendung | |
| EP3173400B1 (de) | Arzneimittel enthaltend kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| EP1073632A1 (de) | Substituierte benzamide,deren herstellung und anwendung als inhibitoren von cystein-proteasen | |
| JP2025511847A (ja) | ラニフィブラノールの結晶形態 | |
| DE60205888T2 (de) | Das citratsalz von 5,8,14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaen | |
| EP1322593A1 (de) | O-substituierte 6-methyl-tramadol-derivate | |
| EP1881956B1 (de) | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen | |
| EP1907350B1 (de) | Salz von fumarsäure und 3- (2-dimethylamino) methyl- ( cyclohex-1-yl) ) phenol un dessen kristalline formen | |
| DE60205504T2 (de) | Zitronensäure salz von einer therapeutischen verbindung und deren pharmazeutischen zusammensetzungen | |
| EP1907351A1 (de) | Hcl-polymorphe von 3 - ( 2- (dimethylamino) methyl- ( cyclohex-i-yl) ) phenol | |
| US20110046230A1 (en) | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof | |
| DE69420425T2 (de) | Die Herstellung von 3-Alkylamino-2-Piperazinylpyridinen | |
| DE102005009217A1 (de) | Phosphatsalze der 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexanverbindungen | |
| US20070032551A1 (en) | Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof | |
| KR20110095545A (ko) | (ｓ)-리바스티그민 오로트산염 및 이를 포함하는 약제학적 조성물 | |
| DE102008046995B4 (de) | 2-Ethoxy-benzoesäurederivat | |
| NZ564902A (en) | 3-[2-(Dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate and the crystalline forms thereof | |
| HK1235765B (en) | Medicaments containing crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8139 | Disposal/non-payment of the annual fee | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20110201 |